Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors [clinicaltrials:NCT01986218]

Bio2RDF uri

Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors [clinicaltrials:NCT01986218]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT01986218

Bio2RDF identifier

NCT01986218

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT01986218

http://www.w3.org/2001/XMLSchema#string

brief summary [clinicaltrials_vocabulary:brief-summary]

The primary purpose of ...... ts with advanced solid tumors

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Phase I Ascending Multiple-Dos ...... cts With Advanced Solid Tumors

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Safety and tolerability of multiple daily doses of BMS-986115 Up to 30 days after the last dose of study medication (approximately 18 months) [clinicaltrials_resource:e2867859a928388ac2ce9621a0107825]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Safety and tolerability of multiple daily doses of BMS-986115 Up to 30 days after the last dose of study medication (approximately 18 months) [clinicaltrials_resource:055f1034545aa5270013a42850bddecd]

Safety and tolerability of multiple daily doses of BMS-986115 Up to 30 days after the last dose of study medication (approximately 18 months) [clinicaltrials_resource:18b5861e1edf05ec6b137a2264a09736]

Safety and tolerability of multiple daily doses of BMS-986115 Up to 30 days after the last dose of study medication (approximately 18 months) [clinicaltrials_resource:4603f19062459822f6c9c89eaab9d318]

Safety and tolerability of multiple daily doses of BMS-986115 Up to 30 days after the last dose of study medication (approximately 18 months) [clinicaltrials_resource:4d23f902f9ba19866be86eb205a419a1]

Safety and tolerability of multiple daily doses of BMS-986115 Up to 30 days after the last dose of study medication (approximately 18 months) [clinicaltrials_resource:727783a66712f0c28664b2242182af99]

Safety and tolerability of multiple daily doses of BMS-986115 Up to 30 days after the last dose of study medication (approximately 18 months) [clinicaltrials_resource:76a089d77c105d71c204c18d11e37623]

Safety and tolerability of multiple daily doses of BMS-986115 Up to 30 days after the last dose of study medication (approximately 18 months) [clinicaltrials_resource:780056353334fd57d459bcfac53ef381]

Safety and tolerability of multiple daily doses of BMS-986115 Up to 30 days after the last dose of study medication (approximately 18 months) [clinicaltrials_resource:8e7aca6abcf35dc9991d1bcd312ec1be]

Safety and tolerability of multiple daily doses of BMS-986115 Up to 30 days after the last dose of study medication (approximately 18 months) [clinicaltrials_resource:a044dd7b993dd6b65dbf58a4f13aa47a]

Safety and tolerability of multiple daily doses of BMS-986115 Up to 30 days after the last dose of study medication (approximately 18 months) [clinicaltrials_resource:b0bc07fd25c9f939702af7b985c2c87c]

completion date [clinicaltrials_vocabulary:completion-date]

2016-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

condition [clinicaltrials_vocabulary:condition]

Various Advanced Cancer [clinicaltrials_resource:1ae7b0ef053fc86bd7322cb38324f74c]

country [clinicaltrials_vocabulary:country]

United States [clinicaltrials_resource:f253efe302d32ab264a76e0ce65be769]

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT01986218 [clinicaltrials_resource:4d6f63603ebf5fd3ee38fc4fb34da87c]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2013-11-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

BMS-986115 [clinicaltrials_resource:68fa69e155271b95f437fe16fa1e0599]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-07-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Bristol-Myers Squibb [clinicaltrials_resource:d4c40cb9f02fd866ab671f3ce45dfa72]

link [clinicaltrials_vocabulary:link]

Investigator Inquiry form [clinicaltrials_resource:2314ff8da7caf18a90888ab03266185c]

FDA Safety Alerts and Recalls [clinicaltrials_resource:3834a9087e4006fa123d334170af525a]

BMS Clinical Trial Information [clinicaltrials_resource:cea6adb53f1855d759c532f4a5cc7e37]

BMS clinical trial educational resource [clinicaltrials_resource:ecfe78d31cdc78071484d9e34e103653]

location [clinicaltrials_vocabulary:location]

Usc/Norris Comprehensive Cancer Center [clinicaltrials_resource:c7c82fae6bae3738c11a2b1253609dc9]

nct id [clinicaltrials_vocabulary:nct-id]

NCT01986218

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

Phase I Ascending Multiple-Dos ...... cts With Advanced Solid Tumors

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

CA002-001

http://www.w3.org/2001/XMLSchema#string

overall contact [clinicaltrials_vocabulary:overall-contact]

Bristol-Myers Squibb [clinicaltrials_resource:3198a154b3c6ab71c470cee213664836]

overall contact backup [clinicaltrials_vocabulary:overall-contact-backup]

Bristol-Myers Squibb [clinicaltrials_resource:8dd8033e871f3c82c52377f2b0914757]

overall official [clinicaltrials_vocabulary:overall-official]

Bristol-Myers Squibb [clinicaltrials_resource:d3a813b7ce44062a0bf05c46ffe9add7]

overall status [clinicaltrials_vocabulary:overall-status]

Recruiting [clinicaltrials_resource:5231dee7156b84b0d1854de1a18dd169]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:80963b1fb71fde54b563469f3c327743]

phase [clinicaltrials_vocabulary:phase]

Phase 1 [clinicaltrials_resource:ee4650e51426c7487977eeea8e7e6850]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2016-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

source [clinicaltrials_vocabulary:source]

Bristol-Myers Squibb [clinicaltrials_resource:d4c40cb9f02fd866ab671f3ce45dfa72]

start date [clinicaltrials_vocabulary:start-date]

2013-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT01986218 study design [clinicaltrials_resource:18c444e9026427edd491d7c3b2864336]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT01986218

verification date [clinicaltrials_vocabulary:verification-date]

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT01986218

http://www.w3.org/2001/XMLSchema#string

title

Phase I Ascending Multiple-Dos ...... cts With Advanced Solid Tumors

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Phase I Ascending Multiple-Dos ...... s [clinicaltrials:NCT01986218]

@en